CL2012002285A1 - Forma cristalina del 4-{(1s,2s)-2-[((r)-4-ciclobutil-2-metilpiperazin-1-il)carbonil]cicclopropil]benzamida; composicion farmaceutica, y su uso para el tratar esquizofrenia, narcolepsia, somnolencia diurna excesiva, obesidad, trastorno cognitivo asociado con esquizonfrenia. - Google Patents

Forma cristalina del 4-{(1s,2s)-2-[((r)-4-ciclobutil-2-metilpiperazin-1-il)carbonil]cicclopropil]benzamida; composicion farmaceutica, y su uso para el tratar esquizofrenia, narcolepsia, somnolencia diurna excesiva, obesidad, trastorno cognitivo asociado con esquizonfrenia.

Info

Publication number
CL2012002285A1
CL2012002285A1 CL2012002285A CL2012002285A CL2012002285A1 CL 2012002285 A1 CL2012002285 A1 CL 2012002285A1 CL 2012002285 A CL2012002285 A CL 2012002285A CL 2012002285 A CL2012002285 A CL 2012002285A CL 2012002285 A1 CL2012002285 A1 CL 2012002285A1
Authority
CL
Chile
Prior art keywords
narcolepsy
methylpiperazin
benzamide
obesity
cyclobutyl
Prior art date
Application number
CL2012002285A
Other languages
English (en)
Inventor
Craig D Collins
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2012002285A1 publication Critical patent/CL2012002285A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Forma sólida I de 4-{(1s,2s)-2-[((r)-4-ciclobutil-2-metilpiperazin-1-il)carbonil]cicclopropil}benzamida; composición farmacéutica, útil para el tratamiento de esquizofrenia, narcolepsia, somnolencia diurna excesiva, obesidad, trastorno por déficit de atención con hiperactividad, dolor, Alzheimer, entre otras.
CL2012002285A 2010-02-18 2012-08-17 Forma cristalina del 4-{(1s,2s)-2-[((r)-4-ciclobutil-2-metilpiperazin-1-il)carbonil]cicclopropil]benzamida; composicion farmaceutica, y su uso para el tratar esquizofrenia, narcolepsia, somnolencia diurna excesiva, obesidad, trastorno cognitivo asociado con esquizonfrenia. CL2012002285A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30558110P 2010-02-18 2010-02-18

Publications (1)

Publication Number Publication Date
CL2012002285A1 true CL2012002285A1 (es) 2013-01-25

Family

ID=44370079

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002285A CL2012002285A1 (es) 2010-02-18 2012-08-17 Forma cristalina del 4-{(1s,2s)-2-[((r)-4-ciclobutil-2-metilpiperazin-1-il)carbonil]cicclopropil]benzamida; composicion farmaceutica, y su uso para el tratar esquizofrenia, narcolepsia, somnolencia diurna excesiva, obesidad, trastorno cognitivo asociado con esquizonfrenia.

Country Status (17)

Country Link
US (1) US20110201622A1 (es)
EP (1) EP2536701A4 (es)
JP (1) JP5746718B2 (es)
KR (1) KR20130034009A (es)
CN (1) CN103140481A (es)
AR (1) AR080203A1 (es)
AU (1) AU2011218490B9 (es)
BR (1) BR112012020780A2 (es)
CA (1) CA2789884A1 (es)
CL (1) CL2012002285A1 (es)
IL (1) IL221430A0 (es)
MX (1) MX2012009537A (es)
NZ (1) NZ602108A (es)
RU (1) RU2012136921A (es)
SG (1) SG183231A1 (es)
TW (1) TW201136898A (es)
WO (1) WO2011102793A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2195293T3 (pl) 2007-08-22 2014-03-31 Astrazeneca Ab Pochodne cyklopropyloamidu
TW201039825A (en) * 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
RU2012136148A (ru) 2010-02-18 2014-03-27 Астразенека Аб Новая кристаллическая форма производного циклопропилбензамида
CN109438423A (zh) * 2018-09-12 2019-03-08 通化师范学院 一种肺癌靶向化合物azd-3759的合成工艺的新方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297170A (es) * 1963-04-04 1900-01-01
US3449427A (en) * 1965-06-03 1969-06-10 Smithkline Corp Aminocyclopropane derivatives of 5h-dibenzo(a,d)cycloheptenes
US3697506A (en) * 1970-08-07 1972-10-10 Pfizer Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor
US3686335A (en) * 1970-12-21 1972-08-22 Smith Kline French Lab 5-vinyl-5h-di benzo(a,d)cycloheptenes
US4432987A (en) * 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US4547505A (en) * 1983-03-25 1985-10-15 Degussa Aktiengesellschaft N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production
DE69013131T2 (de) * 1989-12-29 1995-05-24 Banyu Pharma Co Ltd 2-(2-Cyclopropylpyrrolidin-4-ylthio)carbapenemderivate.
DE4131139A1 (de) * 1991-09-19 1993-03-25 Bayer Ag Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure
PL184611B1 (pl) * 1993-03-12 2002-11-29 Upjohn Co Krystaliczny ceftiofur w postaci wolnego kwasu sposób jego wytwarzania oraz kompozycja farmaceutyczna zawierająca krystaliczny ceftiofur w postaci wolnego kwasu
US6383520B1 (en) * 1998-06-26 2002-05-07 Chugai Seiyaku Kabushiki Kaisha Fine powder of L-α-aminoadipic acid derivative, oral solid preparations containing the same, and method for treatment of bulk powders
US6284761B1 (en) * 1999-01-08 2001-09-04 Neurogen Corporation 1-phenyl-4-(1-[2-aryl]cyclopropyl)methylpiperazines: dopamine receptor ligands
CZ20022332A3 (cs) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
US6521619B2 (en) * 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
HUP0303258A3 (en) * 2001-02-23 2004-06-28 Merck & Co Inc N-substituted nonaryl-heterocyclic nmda/nr2b antagonists and pharmaceutical compositions containing them
EP1442038A4 (en) * 2001-09-26 2005-01-05 Merck & Co Inc CRYSTALLINE FORMS OF CARBAPENEM ANTIBIOTICS AND MANUFACTURING METHOD
US6861432B2 (en) * 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
BR0308525A (pt) * 2002-03-22 2005-02-01 Lg Life Sciences Ltd Formas cristalinas
US20040077618A1 (en) * 2002-10-22 2004-04-22 Bennani Youssef L. Cycloalkylamides and their therapeutic applications
US20040209858A1 (en) * 2002-10-22 2004-10-21 Bennani Youssef L. Cycloalkylamides and their therapeutic applications
PL1615909T3 (pl) * 2003-04-23 2009-01-30 Glaxo Group Ltd Pochodne piperazyny i ich zastosowanie w leczeniu chorób neurologicznych i psychicznych
TWI339206B (en) * 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
DE602006013501D1 (de) * 2005-09-16 2010-05-20 Janssen Pharmaceutica Nv Cyclopropylamine als modulatoren des histamin-h3-rezeptors
JP2009523150A (ja) * 2006-01-13 2009-06-18 エフ．ホフマン−ラ ロシュ アーゲー シクロヘキシルピペラジニルメタノン誘導体及びｈ３受容体調節剤としてのそれらの使用
KR20090024811A (ko) * 2006-06-23 2009-03-09 아보트 러보러터리즈 히스타민 ｈ3 수용체 조절제로서의 사이클로프로필 아민 유도체
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
TW200828371A (en) * 2006-09-21 2008-07-01 Matsushita Electric Ind Co Ltd Chip-type filter
PL2195293T3 (pl) * 2007-08-22 2014-03-31 Astrazeneca Ab Pochodne cyklopropyloamidu
EP2207540B1 (en) * 2007-10-04 2014-02-26 F. Hoffmann-La Roche AG Cyclopropyl aryl amide derivatives and uses thereof
AR070107A1 (es) * 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
TW201039825A (en) * 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
RU2012136148A (ru) * 2010-02-18 2014-03-27 Астразенека Аб Новая кристаллическая форма производного циклопропилбензамида

Also Published As

Publication number Publication date
JP2013520412A (ja) 2013-06-06
AU2011218490B9 (en) 2014-12-18
CA2789884A1 (en) 2011-08-25
IL221430A0 (en) 2012-10-31
CN103140481A (zh) 2013-06-05
NZ602108A (en) 2014-09-26
JP5746718B2 (ja) 2015-07-08
RU2012136921A (ru) 2014-03-27
AU2011218490B2 (en) 2014-11-13
AR080203A1 (es) 2012-03-21
AU2011218490A1 (en) 2012-10-04
US20110201622A1 (en) 2011-08-18
MX2012009537A (es) 2012-08-31
EP2536701A1 (en) 2012-12-26
TW201136898A (en) 2011-11-01
SG183231A1 (en) 2012-09-27
EP2536701A4 (en) 2014-05-07
KR20130034009A (ko) 2013-04-04
BR112012020780A2 (pt) 2016-05-03
WO2011102793A1 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
CL2012003427A1 (es) Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras.
CL2015001358A1 (es) Potenciadores del cftr deuterados
CR20150448A (es) Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos
CL2012001673A1 (es) Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras.
IN2015DN00335A (es)
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2012002259A1 (es) Forma cristalina de 4-{(1s,2s)-2-[84-ciclobutilpiperazin-1-il-carbonil]ciclopropil}benzamida; composicion farmacéutica; y su uso para tratar enfermedades tales como esquizofrenia, narcolepsia, somnolencia diurna excesiva, obesidad, trastornos por deficit de atencion con hiperactividad, dolor, entre otras.
CL2008001921A1 (es) Compuestos derivados de heterociclos sustituidos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ictus, isquemia cerebral, alzheimer, dolor, entre otras.
CL2013003484A1 (es) Compuestos derivados de n-(4-morfolin-2-il)fenil)-1h-pirazol-(3 o 5)-carboxamida o n-(4-piperidin-3-il)fenil)-1h-pirazol-(3 o 5)-carboxamida afines a receptores asociados a taar1; procedimiento de preparacion; composicion farmaceutica y uso en el tratamiento y/o la profilaxis de enfermedades tales como depresion, trastorno bipolar, alzheimer y parkinson, entre otras.
CL2011000668A1 (es) Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras.
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
CL2013001073A1 (es) Compuestos derivados de 6-amino-nicotinamidas sustituidas, como moduladores de kcnq2/3; composicion farmaceutica que los comprende, util para el tratamiento y/o profilaxis de trastornos y/o enfermedades seleccionadas de dolor, epilepsia, ansiedad, enfermedades cognitivas, entre otras.
CL2013002664A1 (es) Compuestos derivados heterociclicos de amina; afines a receptores asociados a mina traza taar1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la depresion, ansiedad, parkinson, trastorno bipolar, de hiperactividad con deficit atencional, relacionados con estres, y otros.
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
PH12015500746A1 (en) Benzamides
CL2012002540A1 (es) Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.
CL2013000756A1 (es) Forma cristalaina del citrato diacido de (4s)-4-(5-fenil-1,3,4-tiadiazol-2-iloxi)-1-azatriciclo[3.3.1.13,7]decano; proceso de preparacion; composicion farmaceutica; y su uso para tratar o prevenir un trastorno de la memoria, un trastorno cognitivo, neurodegeneracion, entre otros.
UY32837A (es) Uso de la 4-aminopiridina para mejorar el deterioro cognitivo en pacientes con desmielinizacion y otros estados del sistema nervioso
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
BR112015013675A2 (pt) composições compreendendo vortioxetina e donepezil
CL2012002285A1 (es) Forma cristalina del 4-{(1s,2s)-2-[((r)-4-ciclobutil-2-metilpiperazin-1-il)carbonil]cicclopropil]benzamida; composicion farmaceutica, y su uso para el tratar esquizofrenia, narcolepsia, somnolencia diurna excesiva, obesidad, trastorno cognitivo asociado con esquizonfrenia.
CL2015000580A1 (es) Compuestos derivados de pirazol carboxamida, moduladores taar; composicion farmaceutica; proceso para obtenerlos; y su uso para el tratamiento terapeutico o profilactico de la depresion, trastornos de ansiedad, trastorno de hiperactividad con deficit de atencion, trastornos psicoticos, esquizofrenia y parkinson, entre otros.